Literature DB >> 6844346

Beneficial effect of verapamil in ischemic acute renal failure in the rat.

D Goldfarb, A Iaina, I Serban, S Gavendo, S Kapuler, H E Eliahou.   

Abstract

To investigate the possible protective effect of Ca2+ blockers in ischemic acute renal failure (ARF), verapamil, in a dose of 10 micrograms/kg body wt/min was administered for 100 min, starting 15 min before the total occlusion of the left renal artery after right nephrectomy in rats. Mean 24-hr creatinine clearance, blood urea, and serum creatinine levels, 24 hr after declamping, were used as a measure of kidney function. These values which were 135 +/- 1.9 microliter/min, 231 +/- 22 mg%, and 2.25 +/- 0.22 mg%, respectively, in the untreated rats, were found to be significantly different, i.e., 326.3 +/- 33.2 microliter/min, P less than 0.001, 112 +/- 25 mg%, P less than 0.001, and 1.26 +/- 0.28 mg%, P less than 0.01, respectively, in the verapamil-treated animals. Increased 24-hr total urine creatinine, sodium, osmolality, and a lower fractional excretion of sodium were also observed in the verapamil-treated rats with ARF. The combination of propranolol 1 mg/kg body wt/min and verapamil 10 micrograms/kg body wt/min for 100 min had no additive effect on renal function. In another group of ARF rats in which verapamil was started after declamping, no alleviating effect was observed. It is concluded that verapamil, an inhibitor of cellular membrane transport, when given prior to the renal ischemia, offers a partial but significant protection in this model of ischemic ARF.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6844346     DOI: 10.3181/00379727-172-41576

Source DB:  PubMed          Journal:  Proc Soc Exp Biol Med        ISSN: 0037-9727


  11 in total

Review 1.  Acute renal failure in the intensive care unit. Part 2.

Authors:  H L Corwin; J V Bonventre
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

2.  Intrarenal infusion of gallopamil in acute renal failure. A preliminary report.

Authors:  D Lumlertgul; O Wongmekiat; C Sirivanichai; P Hundagoon; M Keoplung; J D Conger; R W Schrier
Journal:  Drugs       Date:  1991       Impact factor: 9.546

Review 3.  Cellular mechanism of ischemic acute renal failure: role of Ca2+ and calcium entry blockers.

Authors:  R W Schrier; J Hensen
Journal:  Klin Wochenschr       Date:  1988-09-15

4.  Evidence for role of cytosolic free calcium in hypoxia-induced proximal tubule injury.

Authors:  A Kribben; E D Wieder; J F Wetzels; L Yu; P E Gengaro; T J Burke; R W Schrier
Journal:  J Clin Invest       Date:  1994-05       Impact factor: 14.808

5.  Renal failure in haemorrhagic shock in dogs: salutary effects of the calcium entry blocker felodipine.

Authors:  M S Chintala; B S Jandhyala
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1990-04       Impact factor: 3.000

6.  The influence of long-term infusion of the calcium antagonist diltiazem on postischemic acute renal failure in conscious dogs.

Authors:  K Wagner; G Schultze; M Molzahn; H H Neumayer
Journal:  Klin Wochenschr       Date:  1986-02-03

7.  Protective effect of intrarenal calcium membrane blockers before or after renal ischemia. Functional, morphological, and mitochondrial studies.

Authors:  T J Burke; P E Arnold; J A Gordon; R E Bulger; D C Dobyan; R W Schrier
Journal:  J Clin Invest       Date:  1984-11       Impact factor: 14.808

8.  Protective effect of verapamil on ischaemic renal injury in dogs.

Authors:  M A Sobh; M M el-Sharabasy
Journal:  Int Urol Nephrol       Date:  1987       Impact factor: 2.370

9.  The effect of calcium channel blocker verapamil on gentamicin nephrotoxicity in rats.

Authors:  Nenad Stojiljković; Slavimir Veljković; Dragan Mihailović; Milan Stoiljković; Dragan Radovanović; Pavle Randelović
Journal:  Bosn J Basic Med Sci       Date:  2008-05       Impact factor: 3.363

Review 10.  New approaches to the treatment of acute renal failure.

Authors:  K M Gaudio; N J Siegel
Journal:  Pediatr Nephrol       Date:  1987-07       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.